Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis (MSCsTreatPBC)

Robert Chunhua Zhao, MD, PhD

Status and phase: Unknown; Phase 1

Conditions: Primary Biliary Cirrhosis

Treatments: Drug: ursodeoxycholic acid; Biological: Biological: mesenchymal stem cell

Study type: Interventional

Funder types: Other

Identifiers

NCT01440309

2008BAI59B03/2011AA020119

Details and patient eligibility

About

The study is designed to evaluate the safety and efficacy of intravenous administration of bone marrow derived mesenchymal stem cells for patients with refractory primary biliary cirrhosis (PBC).

Full description

Primary biliary cirrhosis (PBC) is an organ-specific inflammatory disease and characterized by immune mediated destruction of intrahepatic bile ducts, then lead to liver cirrhosis and eventually failure.Currently, ursodeoxycholic acid (UDCA) is the only drug approved by the Food and Drug Administration (FDA). Novel treatment is urgently needed for patients who have an incomplete response to UDCA. Mesenchymal stem cells (MSC) represent a promising tool for cell-based therapies of autoimmune diseases. To explore the therapeutic effect of MSCs for PBC, the investigators plan to conduct an open-label, randomized clinical trial. Patients with PBC will be enrolled and randomly divided into two groups which will receive MSCs and UDCA respectively. The investigators will evaluate the efficacy and safety of MSCs for PBC by comparison of symptom improvement, survival rate and side effects in the two groups.

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• There must be at least two of the following: a concentration in serum of AMAs at titres of 1:40 or higher; an unexplained rise in the amount of alkaline phosphatase of at least 1•5 times the upper limit of normal for more than 24 weeks; and compatible liver histological findings, specifically non-suppurative cholangitis and interlobular bile duct injury.
• Incomplete response to UDCA at 13-15 mg/kg/day, Criteria for the group of complete responders is including: concentrations of alkaline phosphatase less than three times the upper limit of normal, aspartate aminotransferase less than twice the upper limit of normal, and bilirubin less than 17 μmol/L;and normalisation of abnormal concentrations of bilirubin, albumin, or both.
• Liver pathological staging in 2 or3, Histological staging is based on Ludwig's and Scheuer's classifications

Exclusion criteria

• Patients are receiving any other investigational agents within 4 weeks of study entry
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (defined as invasive fungal infection and progressive CMV viremia), symptomatic congestive heart failure (NYH class III and IV), unstable angina pectoris, or cardiac arrhythmia
• In pregnancy or lactation
• Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible
• HCVpositive ，HBSAg positive or with other liver diseases
• Combined with other autoimmune disease
• Expected survival time is less than one year
• Decompensation of liver function（Child B or C）
• Have a history of allergy or Allergic constitution

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

allogenic mesenchymal stem cells (MSCs)

Experimental group

Description:

Patients who have primary biliary cirrhosis.

Treatment:

Biological: Biological: mesenchymal stem cell

ursodeoxycholic acid (UDCA)

Active Comparator group

Description:

Patients who have primary biliary cirrhosis.

Treatment:

Drug: ursodeoxycholic acid